Comparison tool

Octreotide vs Glucagon side-by-side

Stack up to four peptides by evidence status, mechanisms, study dosing, side effects, and references.

Selected (2/4)

OctreotideGlucagon

Share this peptide comparison

Property	Octreotide	Glucagon
Category	Hormonal	Hormonal
Also known as	Sandostatin, Octreotide LAR, Sandostatin LAR, Mycapssa	GlucaGen, Baqsimi
FDA approved	Yes	Yes
Clinical status	FDA Approved - Multiple indications Pre Preclinical I Phase I II Phase II III Phase III IV Phase IV FDA FDA approved	FDA Approved - Hypoglycemia and diagnostic Pre Preclinical I Phase I II Phase II III Phase III IV Phase IV FDA FDA approved
What to expect	Acromegaly, carcinoid tumors, hormone regulation	Hypoglycemia emergency, blood sugar rescue
How it works	Octreotide is presented as a synthetic analog of somatostatin. The evidence describes preferential binding at SSTR2 and SSTR5, followed by intracellular signaling changes involving adenylate cyclase and calcium channels. Those receptor effects are associated with lower secretion of growth hormone, glucagon, insulin, gastrin, and other gut hormones. In the supplied acromegaly context, reduced growth hormone output is linked with lower IGF-1; in carcinoid-related symptoms, the source also connects activity to slower gut motility and reduced splanchnic blood flow.	Glucagon is reported to bind GCGR, a liver-focused G-protein-coupled receptor. Downstream signaling proceeds through Gs, adenylate cyclase, cAMP, and PKA. In the supplied mechanism description, this signaling promotes glycogenolysis and gluconeogenesis, including enzymes such as PEPCK and glucose-6-phosphatase, resulting in increased glucose release from the liver.
Typical dosing	100-500 mcg SC 2-3x daily or LAR monthly · 2-3x daily (SC) or monthly (LAR) · Subcutaneous or intramuscular depot	Limited community data available · See research protocols
Research dosing	50-200 mcg SC 3x daily (immediate) · Long-term / chronic use · Subcutaneous or intramuscular depot	1 mg IM/SC/IV for hypoglycemia · Single dose emergency use · Injection, intranasal, or auto-injector
Typical duration	Long-term / chronic use	Single dose emergency use
Administration	Subcutaneous injection, intramuscular depot, or oral capsule formulations are reported.	Injection, intranasal, or auto-injector
Timing	Morning or as directed With or without food	Morning Take on empty stomach
Evidence level	FDA Approved	FDA Approved
Possible side effects	Nausea Diarrhea Abdominal pain +5 more Gallstones (Source reports 52-63% with long-term use.) Bradycardia Hyperglycemia or hypoglycemia (Source lists blood glucose changes in either direction.) Hypothyroidism Pancreatitis	Nausea (Source reports nausea up to 35%.) Vomiting Headache +5 more Hypertension Tachycardia Allergic reactions Rebound hypoglycemia Contraindicated with pheochromocytoma (Source lists pheochromocytoma as a contraindication.)
Research summary	The supplied evidence characterizes Octreotide as a well-studied peptide drug with human clinical use rather than only laboratory-stage data. It describes long-acting depot use in acromegaly and cites the CHIASMA OPTIMAL phase 3 trial, where oral octreotide maintained biochemical control in about 58% of previously injection-responsive acromegaly patients compared with 19% on placebo over 9 months. The source also reports use in neuroendocrine tumors and carcinoid syndrome, with safety considerations including gallstones, gastrointestinal effects, and altered blood sugar.	The supplied evidence presents glucagon as an established hormone and FDA-approved clinical agent rather than an experimental peptide. It notes severe hypoglycemia rescue as a settled use and describes newer formats such as nasal powder and stable liquid auto-injectors. Mechanistic research cited in the source centers on GCGR and PKA signaling control of hepatic glucose output. The source also links excess glucagon signaling with poorer glucose regulation in diabetes and notes current interest in GCGR activity within dual and triple metabolic agonist drug research.
References	Source Source +2 more Source Source	Source Source +2 more Source Source
Full profile	View Details	View Details

Save this comparison

Keep this research set handy with a free PeptiGuide account.

Save this comparison - free account

Track your peptide journey

Turn research into a private protocol log when you are ready.

Track your peptide journey

Educational use only. This information is aggregated from public research and community reports. It is not medical advice, and dosing details are descriptive, not recommendations. Always consult a qualified healthcare professional.

Property

Octreotide

Glucagon

Category

Hormonal

Also known as

Sandostatin, Octreotide LAR, Sandostatin LAR, Mycapssa

GlucaGen, Baqsimi

FDA approved

Yes

Clinical status

FDA Approved - Multiple indications

Pre
Preclinical
I
Phase I
II
Phase II
III
Phase III
IV
Phase IV
FDA
FDA approved

FDA Approved - Hypoglycemia and diagnostic

Pre
Preclinical
I
Phase I
II
Phase II
III
Phase III
IV
Phase IV
FDA
FDA approved

What to expect

Acromegaly, carcinoid tumors, hormone regulation

Hypoglycemia emergency, blood sugar rescue

How it works

Octreotide is presented as a synthetic analog of somatostatin. The evidence describes preferential binding at SSTR2 and SSTR5, followed by intracellular signaling changes involving adenylate cyclase and calcium channels. Those receptor effects are associated with lower secretion of growth hormone, glucagon, insulin, gastrin, and other gut hormones. In the supplied acromegaly context, reduced growth hormone output is linked with lower IGF-1; in carcinoid-related symptoms, the source also connects activity to slower gut motility and reduced splanchnic blood flow.

Glucagon is reported to bind GCGR, a liver-focused G-protein-coupled receptor. Downstream signaling proceeds through Gs, adenylate cyclase, cAMP, and PKA. In the supplied mechanism description, this signaling promotes glycogenolysis and gluconeogenesis, including enzymes such as PEPCK and glucose-6-phosphatase, resulting in increased glucose release from the liver.

Typical dosing

100-500 mcg SC 2-3x daily or LAR monthly · 2-3x daily (SC) or monthly (LAR) · Subcutaneous or intramuscular depot

Limited community data available · See research protocols

Research dosing

50-200 mcg SC 3x daily (immediate) · Long-term / chronic use · Subcutaneous or intramuscular depot

1 mg IM/SC/IV for hypoglycemia · Single dose emergency use · Injection, intranasal, or auto-injector

Typical duration

Long-term / chronic use

Single dose emergency use

Administration

Subcutaneous injection, intramuscular depot, or oral capsule formulations are reported.

Injection, intranasal, or auto-injector

Timing

Morning or as directed

With or without food

Morning

Take on empty stomach

Evidence level

FDA Approved

Possible side effects

Nausea
Diarrhea
Abdominal pain

+5 more

Gallstones (Source reports 52-63% with long-term use.)
Bradycardia
Hyperglycemia or hypoglycemia (Source lists blood glucose changes in either direction.)
Hypothyroidism
Pancreatitis

Nausea (Source reports nausea up to 35%.)
Vomiting
Headache

+5 more

Hypertension
Tachycardia
Allergic reactions
Rebound hypoglycemia
Contraindicated with pheochromocytoma (Source lists pheochromocytoma as a contraindication.)

Research summary

The supplied evidence characterizes Octreotide as a well-studied peptide drug with human clinical use rather than only laboratory-stage data. It describes long-acting depot use in acromegaly and cites the CHIASMA OPTIMAL phase 3 trial, where oral octreotide maintained biochemical control in about 58% of previously injection-responsive acromegaly patients compared with 19% on placebo over 9 months. The source also reports use in neuroendocrine tumors and carcinoid syndrome, with safety considerations including gallstones, gastrointestinal effects, and altered blood sugar.

The supplied evidence presents glucagon as an established hormone and FDA-approved clinical agent rather than an experimental peptide. It notes severe hypoglycemia rescue as a settled use and describes newer formats such as nasal powder and stable liquid auto-injectors. Mechanistic research cited in the source centers on GCGR and PKA signaling control of hepatic glucose output. The source also links excess glucagon signaling with poorer glucose regulation in diabetes and notes current interest in GCGR activity within dual and triple metabolic agonist drug research.

References

+2 more

+2 more

Full profile